PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision

What happened: A Seeking Alpha analyst rated PolyPid Ltd. ($PYPD) BUY with a $7.25 price target ahead of the November 28, 2026 FDA decision on D-PLEX100. Key numbers: $7.25 price target, 35% upside, $320 million in potential milestone payments, mid-teens-to-mid-20s royalty rates, FDA decision date November 28, 2026. Why it matters: SHIELD II Phase 3 data showed clinically meaningful reductions in surgical site infections, but the prior SHIELD I failure and regulatory risks temper conviction. The Azurity partnership secures U.S. and Canada commercialization.

A Seeking Alpha analyst rated PolyPid Ltd. ($PYPD) BUY with a $7.25 price target ahead of the November 28, 2026 FDA decision on D-PLEX100.

SHIELD II Phase 3 data showed clinically meaningful reductions in surgical site infections, but the prior SHIELD I failure and regulatory risks temper conviction. The Azurity partnership secures U.S. and Canada commercialization.